In Brief: Amarin Perseveres With Vascepa Outcomes Trial, Cochrane Review Reignites Lucentis Cost Debate
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus Acura’s own appeal on abuse-deterrent opioid, TG Therapeutics gets FDA buy-in for ublituximab accelerated approval plan, and Amgen presents more analysis supporting heart failure drug ivabradine after Servier’s failed outcomes trial.
You may also be interested in...
FDA Sticks To Hard Line On Abuse-Deterrent Opioids; Acura Takes A Hit
Acura Pharmaceuticals’ stock fell 11% May 28 after the company revealed that FDA advised an abuse liability study for its hydrocodone/acetaminophen product would not support an abuse liability claim.
Lucentis vs. Avastin Cost Debate Resurfaces With Release Of Medicare Payment Data
Ophthalmologists are among the highest billing specialties listed in the Medicare Part B physician payment data, with Genentech’s Lucentis a strong driver of cost.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.